New research has demonstrated the clear superiority of an oral combination of direct-acting antivirals (DAAs) over a regimen that combines a DAA with pegylated interferon and ribavirin for the treatment of chronic hepatitis C virus (HCV) infection. Results from the C-EDGE Head-to-Head study were presented at the recent EASL International Liver Congress in Barcelona.
If current trends continue, the U.S. may eventually end its HIV epidemic, a mathematical model recently published in AIDS and Behavior shows. In 2009, the average number of people each person with HIV would infect during their lifetime fell below 1, and has now declined to 0.75, the model shows. This means the number of people living with HIV will eventually start to shrink, as more aging HIV-positive people start to die than new people getting infected. For the moment, however, since mortality among people with HIV also continues to fall, the number of people living with the virus continues to grow slowly.
An HIV testing program targeting individuals with acute or early infection likely contributed to a decline in incident or new infections in San Diego after 2008, investigators report in the May 11 online edition of Clinical Infectious Diseases. The Early Test initiative involved negative HIV antibody tests being rescreened using nucleic acid testing (NAT) -- a technique capable of detecting new HIV infections within 7-10 days after exposure.
An individual's HIV viral load set-point is generally reached about a month after plasma viremia is first detectable, according to an analysis published in the May 18 online edition of the New England Journal of Medicine. The RV217 study, which included more than 100 people with acute HIV infection in East Africa and Thailand, found that signs and symptoms were uncommon during the earliest stages of infection, and what happens during this period influences later disease progression.